Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
achondroplasia
Pharma
BioMarin halts dosing, enrollment in 3 midstage Voxzogo studies
BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—approved for a form of dwarfism—across three indications.
Fraiser Kansteiner
Mar 16, 2026 11:26am
FDA approves Ascendis' achondroplasia treatment Yuviwel
Mar 2, 2026 9:25am
BioMarin touts pipeline asset as potential Voxzogo replacement
Aug 5, 2025 11:30am
For $100M, BridgeBio partners with Kyowa Kirin on infigratinib
Feb 7, 2024 12:53pm
BioMarin on its way to turning a profit in 2022
Apr 28, 2022 9:50am
